Ali Nasser retweeted
New @Cell_Metabolism on benefit of intermittent fasting in overweight individuals with metabolic syndrome
A randomized trial showed that the Mediterranean diet, while reducing lipid abnormalities, did not suppress inflammation until intermittent fasting was added
cell.com/cell-metabolism/ful…
Ali Nasser retweeted
Roche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration
@Roche and #HansohPharma have launched their second collaboration focused on developing cancer-fighting #ADCs that could generate more than $15 billion for the Shanghai-based #drugdeveloper
hubs.li/Q04BTKj00
Ali Nasser retweeted
What a pleasure to sit down with @stolaney1 @DanaFarber who has shifted so many paradigms in #breastcancer. Listen to our #ASCODailyNews podcast below that spans #DESTINY-Breast09 #ASCENT-03 & 04, weaving in multiple management pearls along the way!
🎙 @montypal of @cityofhope and @stolaney1 of @DanaFarber discuss optimizing ADCs and managing toxicities in metastatic breast cancer on the latest episode of the #ASCODailyNews Podcast: bit.ly/4saZIZ0
mRNA is no longer just a pandemic technology. 🚀
In 2026, Moderna and Merck reported a 49% reduction in melanoma recurrence or death risk over five years with personalized mRNA therapy [1].
A Phase 3 trial also met key endpoints [2]. This could reshape cancer treatment.
Meanwhile, mRNA-based RSV vaccines are expanding protection to more adults [3]. 🧬
The opportunity is huge. But manufacturing costs, regulatory complexity and unequal access remain barriers.
For biotech leaders, the next competitive edge is scalable, affordable production.
🤔 Should governments prioritize rapid mRNA innovation or equitable access and who should pay for both?
[1] [merck.com/news/moderna-and-m…](merck.com/news/moderna-and-m…)
[2] [nature.com/articles/d41586-0…](nature.com/articles/d41586-0…)
[3] [fda.gov/vaccines-blood-biolo…](fda.gov/vaccines-blood-biolo…)
#mRNA #CancerVaccines #Biotech #VaccineInnovation
Ali Nasser retweeted
NVIDIA unveils partnerships to expand healthcare AI, protein design tools www.mobihealthnews.com/news/nvidia-unveils-partnerships-expand-healthcare-ai-protein-design-tools
Ali Nasser retweeted
#JACCHF analysis: Baseline PAP & change in PAP at 6 months (systolic, diastolic, & mean) were independent predictors of HFH within 2 years. Data from 4 studies using CardioMEMS indicate PAP is an independent predictor of mortality & HFH.
#HeartFailure
bit.ly/4yyPVgU
Ali Nasser retweeted
Tozorakimab improved breathlessness, cough/sputum, and chest symptoms vs. placebo across 52 weeks in patients with #COPD, according to late-breaking OBERON and TITANIA data presented at #CHEST2026 by Frank Sciurba, MD, @PittTweet
Watch here: hubs.ly/Q04BWqHB0
Ali Nasser retweeted
AI agents are writing more code. How can developers ensure that code is correct?
Microsoft Research’s Proof-Driven Development (PDD) Kit explores a more rigorous approach: it translates a developer’s intent into a formal specification, then uses formal verification to prove that generated code meets it.
PDD Kit works with Verus for Rust and is integrated with @GitHubNext’s Chopin, bringing formal methods into an AI-assisted development workflow for teams.
See the work in action at @github Universe, Oct. 28–29, 2026.
Ali Nasser retweeted
Good story - @HarvardHBS OPM62 FTW Luciano and GALY.
🫡🇺🇸
Chocolate is becoming a biomanufacturing story.
Galy just launched WunderHaus, a chocolate made with cocoa grown from cells in tanks in Massachusetts.
Galy is a Boston biotech founded in 2019 by Luciano Bueno and Paula Elbl. It grows plant cells in bioreactors instead of soil.
The investor list is serious. Galy raised a $33 million Series B in 2024, led by Breakthrough Energy Ventures, the fund Bill Gates founded. H&M Group and Inditex joined that round. Earlier backers include Sam Altman's Hydrazine Capital, Material Impact and John Doerr's family office, Eighty Eighty Group.
Luciano first came to SynBioBeta in 2021 and spoke with us in 2023. Back then Galy was known for lab-grown cotton. This year it won Silver at the Edison Awards for its cocoa and cotton platform.
Chocolate companies hit by the climate crisis asked whether the same platform could make cocoa. Galy went from lab to commercial scale in under a year.
How it works:
- Start with a small piece of cocoa bean
- Multiply the cells in brewery-style tanks
- Ferment, roast and grind the harvest into cocoa powder
- Produce in Essex, MA, in repurposed existing infrastructure
Where it stands:
- Cocoa powder self-affirmed GRAS, with FDA notified
- WunderHaus is built for professional kitchens: couverture and baking chocolate
- First customer is Troquet on South in Boston, which stocked its whole kitchen with it
- UAE launch targeted for 2027, backed by a purchase order from a Dubai chocolatier
- Blended with conventional cocoa, with partnerships in the works with growers in Africa and Latin America
Cocoa prices hit an all-time high in 2024. Supply is fragile and weather dependent.
The part I care about most is the platform. A system built for cotton now makes cocoa. Biomanufacturing should work like this: one platform, many crops, production that doesn't depend on weather or farmland.
Congrats to Luciano and the Galy team.
Ali Nasser retweeted
Dimeric granzyme-A mediates the specific recognition and cleavage of full-length GSDMB @NatureComms
nature.com/articles/s41467-0…
Ali Nasser retweeted
Longitudinal Changes in Wearable-Captured Physiology Before Sudden Cardiac Death
👉"Embedding continuous digital physiology monitoring into traditional cardiology has the potential to aid clinicians in timely evaluation and intervention."
📊"The key signal was not any single abnormal value but a coordinated, sustained step-change from the patient’s own baseline that preceded imaging. Data of this kind could complement the episodic measurements cardiovascular care now relies on, informing both when to re-evaluate patients with known heart disease and how wearable heart-rate kinetics might guide their exercise." 👨⚕️
jacc.org/doi/10.1016/j.jacca…
Ali Nasser retweeted
Numerous biotech innovations started with adapting a protein to its non-native context, which often requires substantial experimental optimizations. Here’s a breakdown by our lead, @Xiaowei0402, on a versatile, efficient computational framework to facilitate such adaptations.
Ali Nasser retweeted
We recently introduced LipiGO 🤩: targeted mRNA delivery beyond the liver 🧬
A step toward cell-level precision in medicine: drastically enhanced immune-cell targeting for future in vivo therapies, including CAR-T. biorxiv.org/content/10.1101/…
Ali Nasser retweeted
Hi everyone, we have released a new podcast episode right in time for you to watch (or listen on Apple/Spotify) when traveling to Madrid for #ESMO26! In this episode, I chat with @lateuwen about 0 to 1 (don't tell anyone, its a secret), @OncologyBGLab and what we look for in our fellows, mentorship, leadership, and role of such meetings like ASCO or ESMO Annual meetings. youtube.com/watch?v=sO0CggfT…
Ali Nasser retweeted
I left @Apple to build healthcare that listens and acts early. Today, I'm excited to introduce UniqueHuman.
We're building proactive healthcare agents that handle every step of care for people with chronic conditions.
Our mission is to end chronic suffering. Today, we begin with migraines.
Ali Nasser retweeted
#JACCCardioOnc review:
🫀 Anthracycline cardiotoxicity: more than cardiomyocyte damage!
🔬 Emerging evidence reveals a key role for immune activation, inflammation, & fibrosis.
🎯 Could immune recalibration reshape cardioprotection?
@Massimi78530343
bit.ly/47rbc0S
Ali Nasser retweeted
Are imaging endpoints enough to judge #PulmonaryEmbolism therapies? At #CHEST2026, Samantha Pettigrew, MD, of @TempleHealth @katztemplemed @TempleMedNews reviewed STRATIFY & STORM-PE and made the case for weighing bleeding risk and functional recovery. hcplive.com/view/bleeding-ri… – at Phoenix, AZ
Ali Nasser retweeted
In this #JACCINT meta-analysis of 4 RCTs (n=2,651 #STEMI + multivessel disease), immediate complete revascularization was associated w/ ⬆️ 1-year all-cause mortality vs staged (HR 1.50)—but reduced MI (HR 0.58).
bit.ly/4B9eKm9
Ali Nasser retweeted
Combining targeted therapies may offer a promising way to improve treatment responses in advanced prostate cancer, making biomarker-guided patient selection an important area for further progress. #healthcare #Health
In a randomised phase 2 trial, patients with metastatic hormone sensitive prostate cancer treated with PARP inhibitor talazoparib combined with androgen receptor inhibitor enzalutamide had an improved PSA response vs enzalutamide alone. dlvr.it/TVz69C @quimmateo @VHIO
Ali Nasser retweeted
The number of people developing #dementia each year could more than double by 2050.
A @JAMANeuro study, led by @UNSW’s Centre for Healthy Brain Ageing, pooled individual data from 38,418 people in 22 population-based cohorts across 18 countries and six continents. During more than 287,000 person-years of follow-up, 3,001 participants developed dementia.
An estimated 11.4 million people developed 🧠dementia worldwide in 2023, and annual new cases are projected to reach 24.7 million by 2050. The global standardised incidence was 9.7 new cases per 1,000 person-years.
The burden is uneven. Incidence was higher in #women than men (10.6 vs 8.6 per 1,000 person-years) and markedly higher in low- and middle-income countries than in high-income ones (13.6 vs 8.3). The countries with the fewest resources for diagnosis and care face the steepest rise.
The projection mainly reflects #ageing populations, not rising individual risk. With 14 modifiable risk factors accounting for nearly half of cases, #prevention remains our strongest tool.
jamanetwork.com/journals/jam…

































